Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANT006
MIFTS: 60

Antiphospholipid Syndrome

Categories: Blood diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Antiphospholipid Syndrome

About this section

MalaCards integrated aliases for Antiphospholipid Syndrome:

Name: Antiphospholipid Syndrome 12 77 54 26 38 56 45 15 17 74
Antiphospholipid Antibody Syndrome 12 54 26 64
Hughes Syndrome 54 26 55
Familial Antiphospholipid Syndrome 54 74
Acromegaloid Facial Appearance Syndrome 74
Syndrome, Antiphospholipid, Familial 41
Lupus Anticoagulant, Familial 54
Anti-Phospholipid Syndrome 26
Aps 54

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Immune diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2988
KEGG 38 H01697
MeSH 45 D016736
NCIt 51 C61283
SNOMED-CT 69 19267009 26843008
ICD10 34 D68.61
Sources

Summaries for Antiphospholipid Syndrome

About this section
NINDS : 55 Antiphospholipid syndrome (APS) is an autoimmune disorder caused when antibodies -- immune system cells that fight off bacteria and viruses -- mistakenly attack healthy body tissues and organs.  In APS, specific antibodies activate the inner lining of blood vessels, which leads to the formation of blood clots in arteries or veins.  APS is sometimes called “sticky blood syndrome,” because of the increased tendency to form blood clots in the veins and arteries.  The symptoms of APS are due to the abnormal blood clotting.  Clots can develop in the veins of the legs and lungs, or in the placenta of pregnant women.  One of the most serious complications of APS occurs when a clot forms in the brain and causes a stroke.  Other neurological symptoms include chronic headaches, dementia (similar to the dementia of Alzheimer’s disease), and seizures.  Infrequently, individuals will develop chorea (a movement disorder in which the body and limbs writhe uncontrollably), cognitive dysfunction (such as poor memory), transverse myelitis, depression or psychosis, optic neuropathy, or sudden hearing loss.  In pregnant women, clots in the placenta can cause miscarriages.  APS is diagnosed by the presence of a positive antiphospholipid antibody and either a history of blood clots in an artery or vein or a history of multiple miscarriages or other pregnancy problems.  Some individuals will have a characteristic lacy, net-like red rash called livedo reticularis over their wrists and knees. 

MalaCards based summary : Antiphospholipid Syndrome, also known as antiphospholipid antibody syndrome, is related to catastrophic antiphospholipid syndrome and thrombocytopenia, and has symptoms including unspecified visual loss An important gene associated with Antiphospholipid Syndrome is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Dalteparin and Heparin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are homeostasis/metabolism and cardiovascular system

Disease Ontology : 12 An autoimmune hypersensitivity disease that is characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with characteristic elevated levels of antibodies directed against membrane anionic phospholipids (anticardiolipin).

Genetics Home Reference : 26 Antiphospholipid syndrome is a disorder characterized by an increased tendency to form abnormal blood clots (thromboses) that can block blood vessels. This clotting tendency is known as thrombophilia. In antiphospholipid syndrome, the thromboses can develop in nearly any blood vessel in the body, but most frequently occur in the vessels of the lower limbs. If a blood clot forms in the vessels in the brain, blood flow is impaired and can lead to stroke. Antiphospholipid syndrome is an autoimmune disorder. Autoimmune disorders occur when the immune system attacks the body's own tissues and organs.

NIH Rare Diseases : 54 Antiphospholipid syndrome (APS) is an autoimmune disorder. Signs and symptoms vary, but may include blood clots, miscarriage, rash, chronic headaches, dementia, and seizures. APS occurs when your body's immune system makes antibodies that attack phospholipids. Phospholipids are a type of fat found in all living cells, including blood cells and the lining of blood vessels. Most cases of APS occur in people with no family history of the disorder, however there are rare cases of APS clustering in a family. A widely accepted explanation for APS is that it is caused by a combination of genemutations (making one more susceptible to APS) and an environmental exposure (such as to a virus). Currently there is not a cure for APS. The goal of treatment is to prevent blood clots from forming and to keep existing clots from getting larger.

PubMed Health : 64 About antiphospholipid antibody syndrome: Antiphospholipid (AN-te-fos-fo-LIP-id) antibody syndrome (APS) is an autoimmune disorder. Autoimmune disorders occur if the body's immune system makes antibodies that attack and damage tissues or cells. Antibodies are a type of protein. They usually help defend the body against infections. In APS, however, the body makes antibodies that mistakenly attack phospholipids—a type of fat. Phospholipids are found in all living cells and cell membranes, including blood cells and the lining of blood vessels.When antibodies attack phospholipids, cells are damaged. This damage causes blood clots to form in the body's arteries and veins. (These are the vessels that carry blood to your heart and body.)Usually, blood clotting is a normal bodily process. Blood clots help seal small cuts or breaks on blood vessel walls. This prevents you from losing too much blood. In APS, however, too much blood clotting can block blood flow and damage the body's organs.

Wikipedia : 77 Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune,... more...

Sources

Related Diseases for Antiphospholipid Syndrome

About this section

Diseases in the Antiphospholipid Syndrome family:

Antiphospholipid Syndrome, Familial

Diseases related to Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 557)
# Related Disease Score Top Affiliating Genes
1 catastrophic antiphospholipid syndrome 33.5 ADAMTS13 APOH CD40LG F3 F5 MTHFR
2 thrombocytopenia 31.0 ADAMTS13 APOH F3
3 papilledema 30.4 APOH F2
4 connective tissue disease 30.4 ADAMTS13 APOH CD40LG
5 may-thurner syndrome 30.3 APOH F5
6 sudden sensorineural hearing loss 30.2 APOH F2 F5 MTHFR
7 heparin-induced thrombocytopenia 30.2 CD40LG F10 F3 SERPINC1
8 prothrombin deficiency 30.2 F2 F3
9 endocarditis 30.0 APOH F2 PLAT SERPINC1 VCAM1
10 eclampsia 30.0 F2 MTHFR SERPINC1 THBD
11 pulmonary hypertension 30.0 F3 PLAT THBD VWF
12 carotid artery occlusion 30.0 APOH F5 THBD
13 cerebral sinovenous thrombosis 29.9 APOH F2 F3 F5
14 osteonecrosis 29.9 F2 MTHFR SERPINC1
15 polycythemia vera 29.9 F5 SELP THBD
16 arteritic anterior ischemic optic neuropathy 29.8 F2 F5 MTHFR
17 coronary artery anomaly 29.8 F2 F5 PLAT SELP
18 budd-chiari syndrome 29.8 APOH F2 F3 F5 MTHFR SERPINC1
19 sneddon syndrome 29.8 APOH F2 SERPINC1
20 purpura fulminans 29.8 F2 F3 SERPINC1
21 hepatic infarction 29.7 APOH F2 F3 MTHFR SERPINC1
22 homocysteinemia 29.7 F2 F5 MTHFR SERPINC1
23 retinal vein occlusion 29.7 APOH F2 F5 MTHFR SERPINC1
24 carotid artery dissection 29.7 ADAMTS13 MTHFR PLAT
25 livedoid vasculitis 29.7 APOH F2 MTHFR SERPINC1
26 acute myocardial infarction 29.7 F3 PLAT SELP SERPINC1 VWF
27 thrombocytosis 29.7 F2 F3 SELP SERPINC1
28 branch retinal artery occlusion 29.7 APOH F2 F3 MTHFR SERPINC1
29 coronary thrombosis 29.7 F3 PLAT SERPINC1 VWF
30 raynaud phenomenon 29.7 APOH THBD VWF
31 retinal artery occlusion 29.6 APOH F2 F5 MTHFR SERPINC1
32 nonarteritic anterior ischemic optic neuropathy 29.6 F2 F5 MTHFR SERPINC1
33 ischemic colitis 29.6 APOH F2 F5 SERPINC1
34 essential thrombocythemia 29.6 F2 F3 SELP THBD VWF
35 ischemic optic neuropathy 29.5 APOH F2 F5 MTHFR SERPINC1
36 protein s deficiency 29.4 APOH F2 F3 F5 MTHFR SERPINC1
37 placenta disease 29.4 ANXA5 APOH F3 F5 MTHFR SERPINC1
38 hypertension, essential 29.4 PLAT SELP THBD VWF
39 systemic scleroderma 29.4 CD40LG SELE SELP
40 central retinal vein occlusion 29.4 APOH F2 F5 MTHFR SERPINC1
41 sagittal sinus thrombosis 29.4 F2 F3 F5 SERPINC1
42 rheumatic disease 29.3 APOH CD40LG THBD VCAM1
43 hemolytic uremic syndrome, atypical 1 29.3 ADAMTS13 THBD VWF
44 purpura 29.3 ADAMTS13 APOH F2 F3 SERPINC1 THBD
45 carotid artery thrombosis 29.3 F10 F3 PLAT SELP
46 severe pre-eclampsia 29.3 APOH F5 SERPINC1 VCAM1
47 factor xi deficiency 29.3 F2 F3 SERPINC1 THBD
48 portal vein thrombosis 29.3 APOH F2 F5 MTHFR SELP SERPINC1
49 thrombophlebitis 29.2 APOH F2 F5 MTHFR PLAT SERPINC1
50 patent foramen ovale 29.2 APOH F2 F5 MTHFR PLAT SERPINC1

Graphical network of the top 20 diseases related to Antiphospholipid Syndrome:



Diseases related to Antiphospholipid Syndrome
Sources

Symptoms & Phenotypes for Antiphospholipid Syndrome

About this section

UMLS symptoms related to Antiphospholipid Syndrome:


unspecified visual loss

MGI Mouse Phenotypes related to Antiphospholipid Syndrome:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ADAMTS13 APOH CD40LG F10 F2 F3
2 cardiovascular system MP:0005385 10.26 CD40LG F10 F2 F3 F5 PLAT
3 hematopoietic system MP:0005397 10.23 ADAMTS13 ANXA5 CD40LG F2 F3 PLAT
4 immune system MP:0005387 10.18 ADAMTS13 ANXA5 CD40LG F2 F3 PLAT
5 mortality/aging MP:0010768 10.13 ADAMTS13 APOH CD40LG F10 F2 F3
6 integument MP:0010771 10.02 CD40LG F2 F3 F5 MTHFR PLAT
7 nervous system MP:0003631 9.85 CD40LG F2 F3 F5 MTHFR PLAT
8 liver/biliary system MP:0005370 9.8 F5 MTHFR SELE SELP SERPINC1 THBD
9 reproductive system MP:0005389 9.56 CD40LG F10 F2 MTHFR PLAT SERPINC1
10 vision/eye MP:0005391 9.17 ADAMTS13 F3 MTHFR PLAT SELE SELP
Sources

Drugs & Therapeutics for Antiphospholipid Syndrome

About this section

PubMedHealth treatment related to Antiphospholipid Syndrome: 64

Antiphospholipid antibody syndrome (APS) has no cure. However, medicines can help prevent complications. The goals of treatment are to prevent blood clots from forming and keep existing clots from getting larger.You may have APS and another autoimmune disorder, such as lupus. If so, it's important to control that condition as well. When the other condition is controlled, APS may cause fewer problems.Research is ongoing for new ways to treat APS.

Drugs for Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4,Phase 2,Early Phase 1,Not Applicable 9005-49-6
2
Heparin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable 9005-49-6 46507594 772
3
Enoxaparin Approved Phase 4,Phase 2,Early Phase 1,Not Applicable 9005-49-6 772
4
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
5
leucovorin Approved Phase 4 58-05-9 143 6006
6
Acetaminophen Approved Phase 4,Phase 1,Not Applicable 103-90-2 1983
7
Warfarin Approved Phase 4,Phase 2,Phase 3,Not Applicable 81-81-2 54678486 6691
8
Apixaban Approved Phase 4 503612-47-3 10182969
9
Serine Approved, Nutraceutical Phase 4,Phase 3,Phase 2 56-45-1 5951
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
11 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Vaccines Phase 4,Phase 2,Not Applicable
13 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antibodies, Antiphospholipid Phase 4,Phase 3,Phase 2,Not Applicable
16 Anticoagulants Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
17 calcium heparin Phase 4,Phase 1,Phase 2,Early Phase 1,Not Applicable
18 Heparin, Low-Molecular-Weight Phase 4,Phase 2,Early Phase 1,Not Applicable
19 Fibrinolytic Agents Phase 4,Phase 2,Early Phase 1,Not Applicable
20 Antithrombins Phase 4,Phase 3,Phase 2,Not Applicable
21 Antithrombin III Phase 4,Phase 3,Phase 2,Not Applicable
22
protease inhibitors Phase 4,Phase 3,Phase 2
23 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
24 Serine Proteinase Inhibitors Phase 4,Phase 3,Phase 2
25 Factor Xa Inhibitors Phase 4,Phase 3,Phase 2
26 Nutrients Phase 4
27 Vitamin B Complex Phase 4
28 Vitamin B9 Phase 4
29 Folate Phase 4
30 Trace Elements Phase 4
31 Hematinics Phase 4
32 Vitamins Phase 4
33 Micronutrients Phase 4
34 Analgesics Phase 4,Phase 2,Not Applicable,Early Phase 1
35 Peripheral Nervous System Agents Phase 4,Phase 2,Not Applicable,Early Phase 1
36 Antipyretics Phase 4,Phase 2,Not Applicable,Early Phase 1
37 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable,Early Phase 1
38
Hydroxychloroquine Approved Phase 3,Phase 2,Not Applicable 118-42-3 3652
39
Acenocoumarol Approved, Investigational Phase 3 152-72-7 54676537 9052
40
tannic acid Approved Phase 2, Phase 3,Phase 1 1401-55-4
41
Benzocaine Approved, Investigational Phase 2, Phase 3,Phase 1 1994-09-7, 94-09-7 2337
42 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antimalarials Phase 3,Phase 2,Not Applicable
44 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
45 Antiprotozoal Agents Phase 3,Phase 2,Not Applicable
46 Antiparasitic Agents Phase 3,Phase 2,Not Applicable
47 Autoantibodies Phase 3,Phase 1
48 Antivitamins K Phase 3
49
Aspirin Approved, Vet_approved Phase 1, Phase 2,Phase 2,Early Phase 1,Not Applicable 50-78-2 2244
50
rituximab Approved Phase 2 174722-31-7 10201696

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Rivaroxaban for Antiphospholipid Antibody Syndrome Completed NCT02116036 Phase 4 Rivaroxaban
3 Timing of Initiation of LMWH Administration in Pregnant Women With APS Completed NCT02326051 Phase 4 Enoxaparin;Enoxaparin
4 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
5 Drug Interaction Between Paracetamol and Warfarin Completed NCT01104337 Phase 4 paracetamol;paracetamol;Placebo
6 Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome Recruiting NCT02295475 Phase 4 Apixaban;Warfarin
7 Use of Warfarin After the First Trimester in Pregnant Women With APS Recruiting NCT02303171 Phase 4 Enoxaparin;Warfarin
8 Rivaroxaban for Patients With Antiphospholipid Syndrome Completed NCT02926170 Phase 3 Rivaroxaban;acenocumarol
9 Hydroxychloroquine for Prevention of Recurrent Miscarriage. Recruiting NCT03165136 Phase 3 Hydroxychloroquine;Placebo
10 Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome Not yet recruiting NCT03540810 Phase 3 Hydroxychloroquine;Placebo
11 RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome Not yet recruiting NCT03684564 Phase 2, Phase 3 Rivaroxaban;Warfarin
12 Rivaroxaban in Thrombotic Antiphospholipid Syndrome Terminated NCT02157272 Phase 3 Experimental: Rivaroxaban
13 Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients Terminated NCT01784523 Phase 3 Hydroxychloroquine
14 Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome Unknown status NCT02595346 Phase 2 Hydroxychloroquine;placebo
15 Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss Unknown status NCT00180778 Phase 1, Phase 2 Low dose steroids
16 A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome Completed NCT00537290 Phase 2 Rituximab
17 Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients Completed NCT00674297 Phase 2 Fluvastatin
18 Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome Completed NCT01051778 Phase 2 enoxaparin 40mg plus low dose aspirin;Heparin calcium5,000 U twice daily plus low dose aspirin
19 Aspirin in Asymmetrically Intrauterine Growth Completed NCT03038607 Phase 2 Aspirin
20 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
21 IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy Recruiting NCT03152058 Phase 2 Certolizumab Pegol
22 Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome Active, not recruiting NCT01029587 Phase 2 Eculizumab
23 Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome Terminated NCT02128269 Phase 2
24 Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis Unknown status NCT00230204 Phase 1
25 Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases Terminated NCT00849745 Phase 1
26 Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome Withdrawn NCT00278616 Phase 1
27 Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome Unknown status NCT01661439 low molecular weight heparin (enoxeparine)
28 Antiphospholipid Antibodies and Early Severe Preeclampsia. Unknown status NCT01538121
29 Antiphospholipid Antibodies and Fetal Growth Restriction Unknown status NCT01538134
30 Beneficial Effects of Coenzyme Q10 Treatment on the Mitochondrial Dysfunction and Oxidative Stress Associated to Atherothrombosis Developement in Antiphospholipidid Syndrome Patients Unknown status NCT02218476 Not Applicable CoQ10;Placebo
31 The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome Unknown status NCT01818505
32 Ocular Findings in Women With Primary Antiphospholipid Syndrome Completed NCT03459508
33 Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome Completed NCT01660061
34 Antiphospholipid Syndrome Collaborative Registry (APSCORE) Completed NCT00076713
35 Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin Completed NCT00878137
36 The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations Completed NCT02855047
37 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
38 CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients Completed NCT02139072
39 Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome Completed NCT00010400 Not Applicable Cyclophosphamide;filgrastim
40 Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System) Completed NCT02892565 Not Applicable
41 Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies. Completed NCT00180817
42 CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen Completed NCT01762891 Not Applicable Celecoxib;Acetaminophen;Rofecoxib;placebo
43 Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) Completed NCT01475149
44 Pharmacokinetics of Low Molecular Weight and Unfractionated Heparin in Pregnancy Completed NCT00721591
45 Promising Bimarker Prediction of Outcome of HELLP Syndrome. Completed NCT03246542
46 Clinical Significance of Antiphospholipid Antibodies in Healthy Subjects Completed NCT02803645 Not Applicable
47 Pharmacogenetics of Warfarin in Puerto Ricans. Completed NCT01318057
48 Extra Corporeal Membrane Oxygenation in the Acute Respiratory Distress Syndrome: Utility of a Biomarker to Assess the Membrane Efficiency in Improving Oxygenation Completed NCT02879344 Not Applicable
49 Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) Completed NCT03682419 Not Applicable
50 Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter Recruiting NCT03600636 Not Applicable

Search NIH Clinical Center for Antiphospholipid Syndrome

Cochrane evidence based reviews: antiphospholipid syndrome

Sources

Genetic Tests for Antiphospholipid Syndrome

About this section
Sources

Anatomical Context for Antiphospholipid Syndrome

About this section

MalaCards organs/tissues related to Antiphospholipid Syndrome:

42
Heart, Testes, Brain, Endothelial, Lung, Placenta, Bone
Sources

Publications for Antiphospholipid Syndrome

About this section

Articles related to Antiphospholipid Syndrome:

(show top 50) (show all 3880)
# Title Authors Year
1
Acute myocardial infarction in a young man with large left ventricular thrombus and the antiphospholipid syndrome. ( 30956601 )
2019
2
Clinical and immunological features of antiphospholipid syndrome in the elderly: a retrospective national multicentre study. ( 30608611 )
2019
3
Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome. ( 30616644 )
2019
4
Catastrophic antiphospholipid syndrome causing ST-segment elevation myocardial infarction with non-obstructive coronary arteries. ( 30635301 )
2019
5
Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome. ( 30635311 )
2019
6
Timing of initiation of low-molecular-weight heparin administration in pregnant women with antiphospholipid syndrome: a randomized clinical trial of efficacy and safety. ( 30666167 )
2019
7
Lucio phenomenon mimicking antiphospholipid syndrome: The occurrence of antiphospholipid antibodies in a leprosy patient. ( 30666664 )
2019
8
Pachymeningitis with optic neuropathy associated with extrapulmonary tuberculosis and secondary antiphospholipid syndrome. ( 30685445 )
2019
9
The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. ( 30685523 )
2019
10
Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part II: Obstetric Antiphospholipid Syndrome and Special Situations. ( 30686569 )
2019
11
Recommendations of the Spanish Rheumatology Society for Primary Antiphospholipid Syndrome. Part I: Diagnosis, Evaluation and Treatment. ( 30713012 )
2019
12
Levels of anti-Müllerian hormone in premenopausal women with the antiphospholipid syndrome and its association with the risk of clinical complications. ( 30717622 )
2019
13
Revisiting the role of therapeutic plasma exchange in the management of catastrophic antiphospholipid syndrome. ( 30720923 )
2019
14
Antiphospholipid syndrome and neurofibromatosis type I: a coincidence or new association? ( 30726411 )
2019
15
Tumid lupus erythematosus-like pseudovasculitic lesions in catastrophic antiphospholipid syndrome. ( 30733989 )
2019
16
Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. ( 30747734 )
2019
17
Multimodality imaging in antiphospholipid syndrome. ( 30753375 )
2019
18
Transcranial Doppler findings in antiphospholipid syndrome. ( 30755144 )
2019
19
Outcomes of coronary artery revascularization procedures in patients with antiphospholipid syndrome. ( 30760412 )
2019
20
Prevalence of myocardial infarction with non-obstructive coronary arteries (MINOCA) amongst acute coronary syndrome in patients with antiphospholipid syndrome. ( 30766913 )
2019
21
Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia. ( 30772492 )
2019
22
The European registry on obstetric Antiphospholipid syndrome (EUROAPS): A survey of 1000 consecutive cases. ( 30772493 )
2019
23
High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50 years using the standardized protocol for thrombophilia screening. ( 30780006 )
2019
24
Successful use of sirolimus in a patient with cardiac microangiopathy in primary antiphospholipid syndrome. ( 30794015 )
2019
25
Oral administration of Domain-I of beta-2glycoprotein-I induces immunological tolerance in experimental murine antiphospholipid syndrome. ( 30797663 )
2019
26
Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. ( 30833839 )
2019
27
Thrombotic risk factors in patients with antiphospholipid syndrome: a single center experience. ( 30835035 )
2019
28
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. ( 30844561 )
2019
29
Cerebellar Atrophy and Neurocognitive Disorder as Primary Presentation of Antiphospholipid Syndrome in a Young Male. ( 30854166 )
2019
30
Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome. ( 30858846 )
2019
31
Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. ( 30870459 )
2019
32
Chronic spontaneous coronary artery dissection in association with antiphospholipid syndrome presenting as stable angina. ( 30872339 )
2019
33
Interleukin-17/Interleukin-21 and Interferon-g producing T cells specific for β2 Glycoprotein I in atherosclerosis inflammation of systemic lupus erythematosus patients with antiphospholipid syndrome. ( 30872365 )
2019
34
Reliability of Lupus Anticoagulant and Anti-phosphatidylserine/prothrombin Autoantibodies in Antiphospholipid Syndrome: A Multicenter Study. ( 30891041 )
2019
35
Altered Th17/Treg Ratio in Peripheral Blood of Systemic Lupus Erythematosus but Not Primary Antiphospholipid Syndrome. ( 30894863 )
2019
36
Rare case of catastrophic antiphospholipid syndrome with spontaneous intracranial haemorrhage. ( 30898956 )
2019
37
Catastrophic Antiphospholipid Syndrome as a Cause of Severe Gastrointestinal Bleeding. ( 30904512 )
2019
38
INR Management of an Antiphospholipid Syndrome Patient With Point-of-Care INR Testing. ( 30917725 )
2019
39
Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature. ( 30921233 )
2019
40
Complement in the Pathophysiology of the Antiphospholipid Syndrome. ( 30923524 )
2019
41
Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome. ( 30923525 )
2019
42
Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome. ( 30924705 )
2019
43
Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations. ( 30930907 )
2019
44
Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS). ( 30940667 )
2019
45
The Epidemiology of Antiphospholipid Syndrome. A Population-Based Study. ( 30957430 )
2019
46
A probable case of catastrophic antiphospholipid syndrome: Should high-dose steroids be given in the setting of polymicrobial sepsis? ( 30967955 )
2019
47
Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome. ( 31002781 )
2019
48
Recurrent Stroke Due to Antiphospholipid Syndrome Remitted by Immunotherapy, Not by Anticoagulation Therapy: A Case Report and Literature Review. ( 31007453 )
2019
49
A Coronary Conundrum: Papillary Muscle Rupture and Ischemic Mitral Regurgitation Secondary to Coronary Thromboembolism in Antiphospholipid Syndrome. ( 31010325 )
2019
50
Diagnosing and treating antiphospholipid syndrome: a consensus paper. ( 31012427 )
2019
Sources

Variations for Antiphospholipid Syndrome

About this section

Copy number variations for Antiphospholipid Syndrome from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 160790 22 16300000 24300000 Deletion Hughes'' syndrome
Sources

Expression for Antiphospholipid Syndrome

About this section
Search GEO for disease gene expression data for Antiphospholipid Syndrome.
Sources

Pathways for Antiphospholipid Syndrome

About this section

Pathways related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 67
Show member pathways
 13.01 ANXA5 APOH F10 F2 F3 F5
2
Collagen chain trimerization 67
Show member pathways
 12.57 F10 F2 F3 F5 SERPINC1 THBD
3
Cell surface interactions at the vascular wall 67
Show member pathways
 12.01 F2 SELE SELP THBD
4
Cell adhesion molecules (CAMs) 38
11.9 CD40LG SELE SELP VCAM1
5
Fluid shear stress and atherosclerosis 38
11.85 PLAT SELE THBD VCAM1
6
Formation of Fibrin Clot (Clotting Cascade) 67
Show member pathways
 11.76 F10 F2 F3 F5 PLAT SERPINC1
7
AGE-RAGE signaling pathway in diabetic complications 38
11.62 F3 SELE THBD VCAM1
8
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 CD40LG SELE VCAM1
9
Complement and coagulation cascades 1 38
11.37 F10 F2 F3 F5 PLAT SERPINC1
10
Malaria 38
11.25 CD40LG SELE SELP VCAM1
11
Warfarin Pathway, Pharmacodynamics 62
10.67 F10 F2
Sources

GO Terms for Antiphospholipid Syndrome

About this section

Cellular components related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.8 ADAMTS13 APOH CD40LG F3 PLAT THBD
2 external side of plasma membrane GO:0009897 9.77 ANXA5 CD40LG F2 SELP VCAM1
3 endoplasmic reticulum lumen GO:0005788 9.72 ADAMTS13 F10 F2 F5 SERPINC1
4 extracellular region GO:0005576 9.7 ADAMTS13 ANXA5 APOH CD40LG F10 F2
5 collagen-containing extracellular matrix GO:0062023 9.63 ANXA5 APOH F3 PLAT SERPINC1 VWF
6 extracellular space GO:0005615 9.44 ADAMTS13 APOH CD40LG F10 F2 F3
7 platelet alpha granule GO:0031091 9.43 F5 VWF
8 intrinsic component of external side of plasma membrane GO:0031233 9.4 F10 F3

Biological processes related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.81 SELE SELP THBD VCAM1
2 platelet activation GO:0030168 9.78 ADAMTS13 CD40LG F2 VWF
3 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.7 SELE SELP VCAM1
4 platelet degranulation GO:0002576 9.65 ANXA5 APOH F5 SELP VWF
5 blood coagulation GO:0007596 9.65 ADAMTS13 ANXA5 F10 F2 F3 F5
6 leukocyte tethering or rolling GO:0050901 9.63 SELE SELP VCAM1
7 blood coagulation, intrinsic pathway GO:0007597 9.61 APOH F2 VWF
8 negative regulation of proteolysis GO:0045861 9.58 F2 PLAT
9 calcium-mediated signaling using intracellular calcium source GO:0035584 9.58 SELP VCAM1
10 negative regulation of blood coagulation GO:0030195 9.58 ANXA5 APOH THBD
11 fibrinolysis GO:0042730 9.57 F2 PLAT
12 positive regulation of blood coagulation GO:0030194 9.56 APOH F2
13 plasminogen activation GO:0031639 9.55 APOH PLAT
14 negative regulation of platelet activation GO:0010544 9.54 F2 THBD
15 regulation of blood coagulation GO:0030193 9.54 APOH F2 SERPINC1
16 negative regulation of fibrinolysis GO:0051918 9.5 APOH F2 THBD
17 blood coagulation, extrinsic pathway GO:0007598 9.49 F10 F3
18 leukocyte cell-cell adhesion GO:0007159 9.46 CD40LG SELE SELP VCAM1
19 hemostasis GO:0007599 9.28 ADAMTS13 ANXA5 F10 F2 F3 F5

Molecular functions related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type peptidase activity GO:0008236 9.65 F10 F2 PLAT
2 integrin binding GO:0005178 9.63 ADAMTS13 VCAM1 VWF
3 calcium ion binding GO:0005509 9.63 ADAMTS13 ANXA5 F10 F2 SELP THBD
4 protease binding GO:0002020 9.58 F3 SERPINC1 VWF
5 serine-type endopeptidase activity GO:0004252 9.56 F10 F2 F3 PLAT
6 oligosaccharide binding GO:0070492 9.37 SELE SELP
7 sialic acid binding GO:0033691 9.32 SELE SELP
8 phospholipid binding GO:0005543 9.26 ANXA5 APOH F10 F3
9 heparin binding GO:0008201 9.02 ANXA5 APOH F2 SELP SERPINC1
10 protein binding GO:0005515 10.28 ADAMTS13 ANXA5 APOH CD40LG F10 F2
Sources

Sources for Antiphospholipid Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....